Search

Your search keyword '"Jean-Pierre Devogelaer"' showing total 97 results

Search Constraints

Start Over You searched for: Author "Jean-Pierre Devogelaer" Remove constraint Author: "Jean-Pierre Devogelaer" Topic female Remove constraint Topic: female
97 results on '"Jean-Pierre Devogelaer"'

Search Results

1. Characteristics of Early Paget's Disease in<scp>SQSTM1</scp>Mutation Carriers: Baseline Analysis of the<scp>ZiPP</scp>Study Cohort

2. Sclerostin-Antibody Treatment Decreases Fracture Rates in Axial Skeleton and Improves the Skeletal Phenotype in Growing oim/oim Mice

3. Sclerostin antibody reduces long bone fractures in the oim/oim model of osteogenesis imperfecta

4. Genetic Variation in RIN3 in the Belgian Population Supports Its Involvement in the Pathogenesis of Paget's Disease of Bone and Modifies the Age of Onset

5. Remission Over 3 Years in Patients with Paget Disease of Bone Treated with a Single Intravenous Infusion of 5 mg Zoledronic Acid

6. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial

7. BPS804 Anti-Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial

8. The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club

9. Unmet needs and current and future approaches for osteoporotic patients at high risk of hip fracture

10. Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis

11. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis

12. Indications for a genetic association of a VCP polymorphism with the pathogenesis of sporadic Paget's disease of bone, but not for TNFSF11 (RANKL) and IL-6 polymorphisms

13. Non-pharmacological management of osteoporosis: a consensus of the Belgian Bone Club

14. Fibroblast Growth Factor-23 and Parathyroid Hormone Are Associated with Post-Transplant Bone Mineral Density Loss

15. Biologicals in Osteoporosis: Teriparatide and Parathyroid Hormone in Women and Men

16. Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club

17. Treatment of the vertebral crush fracture syndrome with enteric-coated sodium fluoride tablets and calcium supplements

18. Long-Term Effects on Bone Mineral Density of Different Therapeutic Schemes for Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma during Childhood

19. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: Results at 8 years

20. Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club

21. Relationship between Bone Mineral Density Changes and Fracture Risk Reduction in Patients Treated with Strontium Ranelate

22. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club

23. Vertebral cancellous bone turn-over: Microcallus and bridges in backscatter electron microscopy

24. Spontaneous rupture of the distal iliopsoas tendon: clinical and imaging findings, with anatomic correlations

25. Strontium Ranelate Reduces the Risk of Nonvertebral Fractures in Postmenopausal Women with Osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) Study

26. Comparative Effect of Nimesulide and??Ibuprofen on the Urinary Levels of??Collagen Type II C-Telopeptide Degradation Products and on the Serum Levels of Hyaluronan and Matrix Metalloproteinases-3 and -13 in??Patients with Flare-Up of Osteoarthritis

27. Role of alendronate in therapy for posttraumatic complex regional pain syndrome type I of the lower extremity

28. Evaluation of proposals of Belgian Social Security Institute for reimbursement of bone densitometry tests. Toward a costeffective strategy for osteoporosis screening?

29. Safety and Efficacy of a Novel Salmon Calcitonin (sCT) Technology-Based Oral Formulation in Healthy Postmenopausal Women: Acute and 3-Month Effects on Biomarkers of Bone Turnover

30. A review of the effects of tibolone on the skeleton

31. Irreversible Perforations in Vertebral Trabeculae?

32. Post-renal transplant syndrome of transient lower limb joint pain: description under a tacrolimus-based immunosuppression

33. Patient-specific microarchitecture of vertebral cancellous bone: a peripheral quantitative computed tomographic and histological study

34. Tacrolimus and low-dose steroid immunosuppression preserves bone mass after renal transplantation

35. Scintigraphy using a technetium 99m‐labelled anti‐E‐selectin Fab fragment in rheumatoid arthritis

36. Evaluation of the simple calculated osteoporosis risk estimation (SCORE) in a sample of white women from Belgium

37. Inhomogeneity of human vertebral cancellous bone: systematic density and structure patterns inside the vertebral body

38. Treatment of bone diseases with bisphosphonates, excluding osteoporosis

39. A Risk-Benefit Assessment of Alendronate in the Treatment of Involutional Osteoporosis

40. Primary Prevention of Glucocorticoid-Induced Osteoporosis with Intermittent Intravenous Pamidronate: A Randomized Trial

41. Design for an ipriflavone multicenter European fracture study

42. Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids

43. TRABECULAR AND CORTICAL BONE LOSS IN SYSTEMIC LUPUS ERYTHEMATOSUS

44. A rare case of primary skeletal muscle lymphoma: The value of octreotide scintigraphy

45. Is there a place for bone turnover markers in the assessment of osteoporosis and its treatment?

46. Genome-wide association identifies three new susceptibility loci for Paget's disease of bone

47. [A FRAX model for the assessment of fracture probability in Belgium]

48. Genetic variation in the TNFRSF11A gene encoding RANK is associated with susceptibility to Paget's disease of bone

49. Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial

50. The majority of the genetic risk for Pagets disease of bone is explained by genetic variants close to the **CSF1**, **OPTN**, **TM7SF4**, and **TNFRSF11A** genes

Catalog

Books, media, physical & digital resources